Yang Fan, Wang Tianqi, Liu Yanying
Department of Rheumatology, Beijing Friendship Hospital, Capital Medical University, No.95 Yong'an Road, Xicheng District, Beijing, China.
Clin Rheumatol. 2025 Aug 19. doi: 10.1007/s10067-025-07641-3.
Patients with IgG4-related disease (IgG4-RD) suffer high relapse during long-term treatment, but risk factors associated with relapse are not well established. This study aims to review the potential risk factors and integrate relapse rates of observational studies for IgG4-RD.
Relevant articles published up to January 28, 2025, were comprehensively and systematically identified from PubMed, EMBASE, and Web of Science databases. A systematic review and meta-analysis was performed to estimate pooled odds ratios (ORs), hazard ratios (HRs), and 95% confidence interval (CI).
Twenty-four studies comprising 3797 patients were included. Our findings reveal that a history of allergies (OR: 2.97, 95%CI: 2.07-4.25, P < 0.001), multi-organ involvement (HR: 1.60, 95% CI: 1.23-2.09, P = 0.0005), and decreased complement levels (HR: 2.27, 95% CI: 1.04-4.93, P = 0.04) are significantly associated with relapse. Furthermore, the combination of corticosteroids and immunosuppressants significantly reduces relapse rates (HR: 0.25, 95% CI: 0.10-0.62, P = 0.003). The pooled 12-, 24-, and 36-month relapse rates were 17% (95% CI: 0.10-0.24), 26% (95% CI: 0.22-0.31) and 33% (95% CI: 0.26-0.39), respectively.
This meta-analysis indicated that a history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. Besides, corticosteroid combined with immunosuppressant therapy could decrease relapse rates. Key Points • A history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. • The combination of corticosteroids and immunosuppressants could reduces relapse rates of IgG4-RD. • The 12-, 24- and 36-month relapse rates of IgG4-RD were 17%, 26% and 33%, respectively.
IgG4相关性疾病(IgG4-RD)患者在长期治疗期间复发率较高,但与复发相关的危险因素尚未完全明确。本研究旨在回顾潜在的危险因素,并汇总IgG4-RD观察性研究的复发率。
从PubMed、EMBASE和Web of Science数据库中全面、系统地检索截至2025年1月28日发表的相关文章。进行系统评价和荟萃分析,以估计合并比值比(OR)、风险比(HR)和95%置信区间(CI)。
纳入了24项研究,共3797例患者。我们的研究结果显示,过敏史(OR:2.97,95%CI:2.07-4.25,P<0.001)、多器官受累(HR:1.60,95%CI:1.23-2.09,P=0.0005)和补体水平降低(HR:2.27,95%CI:1.04-4.93,P=0.04)与复发显著相关。此外,糖皮质激素和免疫抑制剂联合使用可显著降低复发率(HR:0.25,95%CI:0.10-0.62,P=0.003)。汇总的12个月、24个月和36个月复发率分别为17%(95%CI:0.10-0.24)、26%(95%CI:0.22-0.31)和33%(95%CI:0.26-0.39)。
这项荟萃分析表明,过敏史、多器官受累和补体水平降低是IgG4-RD复发的危险因素。此外,糖皮质激素联合免疫抑制剂治疗可降低复发率。要点•过敏史、多器官受累和补体水平降低是IgG4-RD复发的危险因素。•糖皮质激素和免疫抑制剂联合使用可降低IgG4-RD的复发率。•IgG4-RD的12个月、24个月和36个月复发率分别为17%、26%和33%。